The UK MHRA granted marketing authorisation to Eli Lilly's oral GLP-1 receptor agonist orforglipron Foundayo on 10 August 2026, enabling private prescriptions for weight management and type 2 diabetes. The dual-indication approval, based on six ATTAIN and ACHIEVE trials, makes the UK the first…
The Medicines and Healthcare products Regulatory Agency granted marketing authorisation to Eli Lilly's oral GLP-1 receptor agonist orforglipron Foundayo on 10 August 2026, clearing the drug for private prescription in the United Kingdom. The decision makes the UK the first country in Europe where the product is available, according to Eli Lilly, and marks the second time the MHRA has cleared an oral drug in the GLP-1 class, following Novo Nordisk's Wegovy semaglutide pill in June. The public record describes the UK as thought to be the third country worldwide to clear orforglipron for marketing, after the United States and the United Arab Emirates; the US approval came in April.
A marketing authorisation is the UK licence to place a medicine on the market. It rests on an assessment of quality, safety, and efficacy for the specific indications named in the licence, and it carries no automatic right to public funding. The sequence around orforglipron shows how the two questions, whether a drug may be sold and whether the state will pay for it, run on separate tracks. The US Food and Drug Administration cleared orforglipron in April, the MHRA authorised it on 10 August, Eli Lilly announced private availability in August, and the National Institute for Health and Care Excellence NICE has a provisional date of mid-November for preliminary guidance on overweight and obesity. Each step is a different kind of decision, made by a different body on different evidence standards.
The authorisation covers two indications. In weight management, orforglipron is licensed for adults with a body mass index of 30 kg/m2 or higher, or from 27 kg/m2 to below 30 kg/m2 when at least one weight-related comorbidity is present, in both cases as an adjunct to a reduced-calorie diet and increased physical activity. In type 2 diabetes, it is licensed for adults with insufficiently controlled disease, as an adjunct to diet and exercise, either as monotherapy or in combination with other diabetes medicines. That dual scope is the structural difference between orforglipron and the other oral agent in the class at the MHRA: the Wegovy pill was cleared in June for weight loss only, so the two products are not directly commensurate.
"The UK is the first country in Europe where Foundayo is now available," said Khalil Asmar, Vice President of Cardiometabolic Health at Lilly Northern Europe. "We're pleased that this means there is another oral treatment option for eligible UK patients alongside licensed injectable treatments," Asmar said. Eli Lilly announced in August that Foundayo could be prescribed privately to eligible adults, meaning patients can obtain it through private clinicians at their own expense while the NICE appraisal for NHS use remains pending.
The MHRA's decision rests on six clinical trials:
The weight-management indication defines two qualifying populations. Adults with a BMI of 30 kg/m2 or higher qualify without further criteria, while adults with a BMI from 27 kg/m2 to below 30 kg/m2 qualify when at least one weight-related comorbidity is present. The thresholds track the standard clinical definitions of obesity and overweight, and the comorbidity requirement is what restricts the lower band to patients at elevated metabolic risk. The public record does not enumerate which conditions qualify as weight-related comorbidities for this purpose, nor does it say which combination partners were studied in the ACHIEVE programme; those details sit in the trial publications rather than in the authorisation itself.
The authorisation frames the drug as an adjunct to a reduced-calorie diet and increased physical activity. That is regulatory language with practical content: the medicine is licensed as part of a lifestyle intervention, not as a substitute for one, and prescribers are expected to maintain the dietary and activity components of the treatment plan.
The diabetes indication is broader still. It covers adults whose glycaemic control is insufficiently managed, used alongside diet and exercise, as monotherapy or in combination with other glucose-lowering medicines. A drug that can be introduced at any point in a treatment sequence, including as first pharmacotherapy, is positioned differently from one that enters only after other agents have failed. The indication also signals where the oral class is heading. The first oral GLP-1 product at the MHRA, the Wegovy pill, was restricted to weight loss. Orforglipron arrives with type 2 diabetes included from the start, returning the class to the territory where GLP-1 biology was first exploited clinically while retaining the weight-management claim that has generated the most demand.
The public record states that six trials support the authorisation and says little more. For most of them there is no trial design, no enrolled population, no sample size, no duration, and no efficacy or safety data. The gap is material. A clinician who wants to weigh orforglipron against oral semaglutide on glycaemic control, weight loss, gastrointestinal tolerability, or discontinuation rates cannot do so from the registration record as it stands. Of the six named trials, only one has a peer-reviewed report in the indexed literature.
That trial is ACHIEVE-3 , which appeared in The Lancet on 21 March 2026, weeks before the FDA approval in April. Its published form describes a multinational, multicentre, non-inferiority , open-label, randomised phase 3 trial comparing once-daily oral orforglipron with oral semaglutide in adults with type 2 diabetes. A non-inferiority design asks a specific question: whether the new drug preserves a clinically acceptable share of the benefit of an established comparator, judged against a pre-specified margin. That is the natural question when the class already contains a licensed oral agent. Non-inferiority does not test whether the new drug is superior, and the open-label design, in which patients and investigators know the assigned treatment, is a recognised limitation where outcomes are patient-reported, as nausea, satiety, and weight are. The two tablets cannot easily be masked from each other, so the design trade-off is visible in the protocol itself.
The indexed literature around orforglipron is small but active. It includes a meta-analysis and systematic review of orforglipron's efficacy and safety on cardiometabolic outcomes, published on 20 February in Cardiovascular Diabetology and Endocrinology Reports , and a review of incretin modulation in cardiovascular and renal outcomes, published on 1 March in Diabetes Therapy . Both predate the ACHIEVE-3 paper, so the synthesis literature is arriving in real time, before the individual trial results are fully in print. Basic-science work is visible too: a study modelling G protein-biased agonism through GLP-1 receptor C-terminal mutations, published on 1 March in Molecular Metabolism , and a paper describing a humanised GLP-1 receptor mouse model for translational drug development, published on 1 February in EBioMedicine . The meta-analysis matters as early evidence aggregation; the field is attempting to synthesise orforglipron data while the registration package is still the main public reference.
What a registration design of this kind can establish, and cannot, deserves precision. Randomised trials can show efficacy against placebo or an active comparator under controlled conditions, and they can generate adverse-event data at scale. They cannot establish long-term safety, rare-event profiles, or comparative effectiveness across the whole class; those come from post-marketing surveillance, real-world studies, and later head-to-head work. Until the ATTAIN and ACHIEVE results are published in full, the evidentiary foundation for orforglipron in the public domain will remain thinner than the regulatory action might suggest.
A marketing authorisation is a national licence, not a funding decision. The MHRA's decision certifies that orforglipron meets UK standards for quality, safety, and efficacy and may be placed on the market. In England, whether the state pays for it is NICE's task, and the appraisal was incomplete at launch. Lilly is working with NICE on the assessment for potential NHS use, but the provisional date of mid-November applies to preliminary guidance on orforglipron for overweight and obesity; the public record gives no equivalent date for an appraisal of the type 2 diabetes indication. Preliminary guidance is a consultative draft, open to revision after stakeholder comment, and it does not establish what final guidance will contain.
The distinction between authorisation and appraisal is fundamental. The regulator asks whether a medicine works and is acceptably safe to market; the health technology assessment body asks whether it works well enough, at the price, to justify public funding. The two can diverge, and the timetable shows why. The FDA cleared orforglipron in April, and the drug is commercially available in the United States and the UAE. The MHRA authorised it on 10 August. NICE's provisional mid-November date for preliminary guidance is the next visible milestone, and final guidance could take months more. The claim that the UK is the third country to clear the drug is also hedged in the public record, which says the UK is thought to be third. That hedge is appropriate: the order of national clearances is a matter of each regulator's own record, and further decisions, where they come, will change the count.
Private access also changes who reaches the drug first. Cost falls on the patient, so early availability skews toward people who can pay. NHS access, if it comes, will follow a cost-effectiveness assessment, and that assessment may narrow the eligible population. The public record names NHS England as the relevant body and specifies nothing about Wales, Scotland, or Northern Ireland, so the picture across the UK is incomplete by design.
The regulatory sequence is itself a signal. The US approval in April, commercial availability in the US and UAE, and the UK authorisation in August place orforglipron's rollout ahead of most European markets. The MHRA acts as a standalone national regulator, and its June clearance of the Wegovy pill for weight loss only, followed by its August clearance of orforglipron for two indications, leaves the UK with two oral GLP-1 products of different scope and different chemistry. Further European decisions would run through the European Medicines Agency, a separate route with its own timetable, and no dates for it are on the public record.
The therapeutic rationale runs through incretin biology. GLP-1 is an incretin hormone released from intestinal L cells in response to food. It potentiates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, slows gastric emptying, and increases satiety through actions in the gut and the central nervous system. Because insulin secretion is glucose-dependent, the class carries a relatively low intrinsic risk of hypoglycaemia compared with insulin or sulfonylureas. The same mechanisms, particularly the effects on gastric emptying and appetite, are what produce weight loss. That the two licensed indications rest on the same biology is not incidental: the glucose effect and the weight effect are both downstream of a single receptor, which is why one molecule can plausibly carry both claims.
Orforglipron activates the GLP-1 receptor, the same target as semaglutide, but it is not a peptide. It is a non-peptide small-molecule agonist , taken once daily, designed for oral…
Peptides referenced: Semaglutide, Orforglipron, Glucagon, GLP-1.
Related reading: Seventh Victorian Case Links Counterfeit Retatrutide to Liver Toxicity, AI-designed oral peptides get first commercial test in $100M deal, Meant launches LegitScript-certified GLP-1 telehealth platform, NCI tests neoantigen vaccine in metastatic triple-negative breast cancer.